Alexithymia in Patients with Ménière Disease: A Possible Role on Anxiety and Depression
Abstract
:1. Introduction
1.1. Definite MD
- A.
- Two or more spontaneous episodes of vertigo each lasting 20 min to 12 h;
- B.
- Audiometrically documented low- to medium-frequency sensorineural hearing loss in one ear, defining the affected ear on at least one occasion before, during or after one of the episodes of vertigo;
- C.
- Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear;
- D.
- Not better accounted for by another vestibular diagnosis.
1.2. Probable MD
- A.
- Two or more episodes of vertigo or dizziness, each lasting 20 min to 24 h;
- B.
- Fluctuating aural symptoms (hearing, tinnitus or fullness) in the affected ear;
- C.
- Not better accounted for by another vestibular diagnosis.
2. Materials and Methods
2.1. Sample
2.2. Questionnaires
2.3. Statistical Analyses
3. Results
3.1. Socio-Demographic Characteristics of the Sample
3.2. Features of Ménière Disease
3.3. Psychological Variables of the Sample and Comparison with Normative Data
3.4. Division of the Sample According to the Threshold for Alexithymia
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Kutlubaev, M.A.; Pyykko, I.; Hardy, T.A.; Gürkov, R. Menière’s disease. Pract Neurol. 2020. [Google Scholar] [CrossRef]
- Requena, T.; Gazquez, I.; Moreno, A.; Batuecas, A.; Aran, I.; Soto-Varela, A.; Santos-Pérez, S.; Perez, N.; Pérez-Garrigues, H.; López-Nevot, A.; et al. Allelic variants in TLR10 gene may influence bilateral affectation and clinical course of Meniere’s disease. Immunogenetics 2013, 65, 345–355. [Google Scholar] [CrossRef] [PubMed]
- Frejo, L.; Giegling, I.; Teggi, R.; Lopez-Escamez, J.A.; Rujescu, D. Genetics of vestibular disorders: Pathophysiological insights. J. Neurol. 2016, 263 (Suppl. 1), S45–S53. [Google Scholar] [CrossRef] [Green Version]
- Teggi, R.; Fabiano, B.; Recanati, P.; Limardo, P.; Bussi, M. Case reports on two patients with episodic vertigo, fluctuating hearing loss and migraine responding to prophylactic drugs for migraine. Menière’s disease or migraine-associated vertigo? Acta Otorhinolaryngol. 2010, 30, 217. [Google Scholar]
- Lopez-Escamez, J.A.; Carey, J.; Chung, W.-H.; Goebel, J.A.; Magnusson, M.; Mandalà, M.; Newman-Toker, D.E.; Strupp, M.; Suzuki, M.; Trabalzini, F.; et al. Diagnostic criteria for Menière’s disease. J. Vestib. Res. 2015, 25, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balaban, C.D. Neural substrates linking balance control and anxiety. Physiol. Behav. 2002, 77, 469–475. [Google Scholar] [CrossRef]
- Best, C.; Eckhardt-Henn, A.; Tschan, R.; Dieterich, M. Psychiatric morbidity and comorbidity in different vestibular vertigo syndromes. Results of a prospective longitudinal study over one year. J. Neurol. 2009, 256, 58–65. [Google Scholar] [CrossRef]
- Kirby, S.E.; Yardley, L. Cognitions associated with anxiety in Ménière’s disease. J. Psychosom. Res. 2009, 66, 111–118. [Google Scholar] [CrossRef] [PubMed]
- Nemiah, J.C.; Freyberger, H.; Sifneos, P.E. Alexithymia: A view of the psychosomatic process. In Modern Trends in Psychosoma Medicine; Hill, O.W., Ed.; Butterworth: London, UK, 1976; Volume 2, pp. 26–34. [Google Scholar]
- Moriguchi, Y.; Ohnishi, T.; Lane, R.D.; Maeda, M.; Mori, T.; Nemoto, K.; Matsuda, H.; Komaki, G. Impaired self-awareness and theory of mind: An fMRI study of mentalizing in alexithymia. NeuroImage 2006, 32, 1472–1482. [Google Scholar] [CrossRef]
- Willemsen, R.; Roseeuw, D.; Vanderlinden, J. Alexithymia and dermatology: The state of the art. Int. J. Dermatol. 2008, 47, 903–910. [Google Scholar] [CrossRef] [PubMed]
- Taylor, G.J.; Bagby, R.M. New Trends in Alexithymia Research. Psychother. Psychosom. 2004, 73, 68–77. [Google Scholar] [CrossRef]
- Bagby, R.; Parker, J.D.; Taylor, G.J. The twenty-item Toronto Alexithymia scale—I. Item selection and cross-validation of the factor structure. J. Psychosom. Res. 1994, 38, 23–32. [Google Scholar] [CrossRef]
- Bressi, C.; Taylor, G.; Parker, J.; Bressi, S.; Brambilla, V.; Aguglia, E.; Allegranti, I.; Bongiorno, A.; Giberti, F.; Bucca, M.; et al. Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: An Italian multicenter study. J. Psychosom. Res. 1996, 41, 551–559. [Google Scholar] [CrossRef]
- Skevington, S.; Lotfy, M.; O’Connell, K.; WHOQOL Group. The World Health Organization’s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual. Life Res. 2004, 13, 299–310. [Google Scholar] [CrossRef] [PubMed]
- Zigmond, A.S.; Snaith, R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 1983, 67, 361–370. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Costantini, M.; Musso, M.; Viterbori, P.; Bonci, F.; Del Mastro, L.; Garrone, O.; Venturini, M.; Morasso, G. Detecting psychological distress in cancer patients: Validity of the Italian version of the Hospital Anxiety and Depression Scale. Supportive Care Cancer 1999, 7, 121–127. [Google Scholar] [CrossRef]
- Cohen, S.; Kamarck, T.; Mermelstein, R. A global measure of perceived stress. J. Health Soc. Behav. 1983, 24, 386–396. [Google Scholar] [CrossRef]
- Cohen, S.; Miller, G.E.; Rabin, B.S. Psychological Stress and Antibody Response to Immunization: A Critical Review of the Human Literature. Psychosom. Med. 2001, 63, 7–18. [Google Scholar] [CrossRef] [PubMed]
- Malarkey, W.B.; Pearl, D.K.; Demers, L.M.; Kiecolt-Glaser, J.K.; Glaser, R. Influence of academic stress and season on 24-hour mean concentrations of ACTH, cortisol, and β-endorphin. Psychoneuroendocrinology 1995, 20, 499–508. [Google Scholar] [CrossRef]
- Van Eck, M.M.; Nicolson, N.A. Perceived stress and salivary cortisol in daily life. Ann. Behav. Med. 1994, 16, 221–227. [Google Scholar] [CrossRef]
- Fossati, A. Scala per lo Stress Percepito, Traduzione Italiana a cura di Andrea Fossati, Università Vita-Salute San Raffaele, Milano. Unpublished. 2010.
- Carver, C.S.; Scheier, M.F.; Weintraub, J.K. Assessing coping strategies: A theoretically based approach. J. Personal. Soc. Psychol. 1989, 56, 267–283. [Google Scholar] [CrossRef]
- Sica, C.; Novara, C.; Dorz, S.; Sanavio, E. Coping Orientations to Problems Experienced: Traduzione e adattamento italiano. Boll. Psicol. Appl. 1997, 223, 25–34. [Google Scholar]
- Infrasca, R. Alexithymia, Neurovegetative Arousal and Neuroticism. An experimental study. Psychother. Psychosom. 1997, 66, 276–280. [Google Scholar] [CrossRef]
- Fukunishi, I.; Sei, H.; Morita, Y.; Rahe, R.H. Sympathetic activity in alexithymics with mother’s low care. J. Psychosom. Res. 1999, 46, 579–589. [Google Scholar] [CrossRef]
- Gündel, H.; Greiner, A.; Ceballos-Baumann, A.O.; Von Rad, M.; Förstl, H.; Jahn, T. Increased level of tonic sympathetic arousal in high versus low alexithymic cervical dystonia patients. Psychother. Psychosom. Med. Psychol. 2002, 52, 461–468. [Google Scholar] [CrossRef]
- Guilbaud, O.; Corcos, M.; Hjalmarsson, L.; Loas, G.; Jeammet, P. Is there a psychoneuroimmunological pathway between alexithymia and immunity? Immune and physiological correlates of alexithymia. Biomed. Pharmacother. 2003, 57, 292–295. [Google Scholar] [CrossRef]
- Larsen, J.K.; Brand, N.; Bermond, B.; Hijman, R. Cognitive and emotional characteristics of alexithymia: A review of neurobiological studies. J. Psychosom. Res. 2003, 54, 533–541. [Google Scholar] [CrossRef]
- Honkalampi, K.; Koivumaa-Honkanen, H.; Antikainen, R.; Haatainen, K.; Hintikka, J.; Viinamäki, H. Relationships Among Alexithymia, Adverse Childhood Experiences, Sociodemographic Variables, and Actual Mood Disorder: A 2-Year Clinical Follow-Up Study of Patients with Major Depressive Disorder. J. Psychosom. Res. 2004, 45, 197–204. [Google Scholar] [CrossRef] [PubMed]
- Lumley, M.A.; Neely, L.C.; Burger, A.J. The Assessment of Alexithymia in Medical Settings: Implications for Understanding and Treating Health Problems. J. Personal. Assess. 2007, 89, 230–246. [Google Scholar] [CrossRef] [Green Version]
N = 179 | ||
---|---|---|
Frequency (%) | ||
Laterality | Left | 69 (38.5%) |
Right | 64 (35.8%) | |
Bilateral | 46 (25.7%) | |
Onset age | Mean (SD) y.o. | 37.3 (11.7) |
Range | 6–70 | |
Number of crises in the last year | Mean (SD) | 5.75 (8.1) |
Range | 0–50 |
Mean (SD) | Score Range | |
---|---|---|
TAS–20 | ||
DIF (difficulty in identifying feelings) | 21.7 (6.7) | 7–35 |
DDF (difficulty in describing feelings) | 13.2 (4.4) | 5–25 |
EOT (externally oriented thinking) | 18.2 (4.5) | 8–40 |
Total | 53.2 (11.5) | 20–100 |
WHOQOL | ||
Overall quality of life | 2.97 (0.96) | 1–5 |
General health | 2.6 (0.92) | 1–5 |
DOM 1: Physical health | 52.64 (16.31) | 0–100 |
DOM 2: Psychological | 49.61 (13.11) | 0–100 |
DOM 3: social relationships | 55.27 (19.91) | 0–100 |
DOM4: environment | 55.72 (14.22) | 0–100 |
HADS | ||
Anxiety | 9.1 (4.2) | 0–21 |
Depression | 6.3 (4) | 0–21 |
PSS | ||
Total stress | 19.93 (7.1) | 0–40 |
Perceived stress last week | 5.74 (2.6) | 0–10 |
Perceived stress last month | 6.2 (2.6) | 0–10 |
COPE | ||
Positive reinterpretation and growth | 10.2 (2.85) | 4–16 |
Mental disengagement | 8.65 (2.2) | 4–16 |
Focus on and venting of emotions | 9.15 (2.37) | 4–16 |
Use of instrumental social support | 9.33 (3.17) | 4–16 |
Active coping | 10.49 (2.55) | 4–16 |
Denial | 5.9 (1.9) | 4–16 |
Religious coping | 8.4 (4.17) | 4–16 |
Humor | 7.35 (3.2) | 4–16 |
Behavioral disengagement | 6.86 (2.4) | 4–16 |
Restraint | 9.6 (2.6) | 4–16 |
Use of emotional social support | 8.9 (3.28) | 4–16 |
Substance use | 5.2 (2.2) | 4–16 |
Acceptance | 10.74 (3.16) | 4–16 |
Suppression of competing activities | 8.7 (2.3) | 4–16 |
Planning | 10.36 (2.9) | 4–16 |
MD | Normative Value | t-test | |
---|---|---|---|
DIF (difficulty in identifying feelings) | 21.7 (6.7) | 14.6 (6) | T (178) = 14.3; p < 0.001 |
DDF (difficulty in describing feelings) | 13.2 (4.4) | 13.1 (4.8) | n.s. |
EOT (externally oriented thinking) | 18.2 (4.5) | 17.1 (4.9) | T (178) = 3.3; p < 0.005 |
TOT | 53.2 (11.5) | 44.7 (11.3) | T (178) = 9.8; p < 0.001 |
Non-Alexithymic | Alexithymic | ||
---|---|---|---|
M (sd) | M (sd) | t-test | |
Age | 48.38 (11.32) | 49.17 (11.71) | n.s. |
Onset age | 37.03 (11.12) | 37.49 (12.18) | n.s. |
Number of crises in the last year | 4.77 (5.49) | 6.64 (9.84) | n.s |
Non-Alexithymic | Alexithymic | ||
---|---|---|---|
M (sd) | M (sd) | t-test | |
WHOQOL | |||
Overall quality of life | 3.14 (0.94) | 2.86 (0.97) | n.s |
General health | 2.66 (0.97) | 2.55 (0.9) | n.s. |
DOM 1: Physical health | 55.36 (16.8) | 50.71 (15.7) | n.s |
DOM 2: Psychological | 53.14 (13.1) | 47.12 (12.6) | T (177) = 3.09; p < 0.005 |
DOM 3: social relationships | 61.39 (20.2) | 50.96 (18.6) | T (177) = 3.56; p < 0.001 |
DOM4: environment | 57.7 (16.05) | 54.29 (12.7) | n.s |
HADS | |||
Anxiety | 7.42 (3.8) | 10.27 (4.2) | T (177) = −4.68; p < 0.001 |
Depression | 4.54 (3.6) | 7.58 (3.9) | T (177) = −5.31; p < 0.001 |
PSS | |||
Total stress | 17.1 (6.4) | 21.9 (6.9) | T (151) = −4.37; p < 0.001 |
Perceived stress last week | 5.16 (2.9) | 6.13 (2.3) | T (151) = −2.31; p < 0.05 |
Perceived stress last month | 5.44 (2.7) | 6.73 (2.3) | T (151) = −3.12; p < 0.005 |
COPE | |||
Positive reinterpretation and growth | 11.5 (2.6) | 9.33 (2.7) | T (157) = 5.08; p < 0.001 |
Mental disengagement | 8.5 (2.5) | 8.8 (1.9) | n.s. |
Focus on and venting of emotions | 9.5 (2.5) | 8.9 (2.2) | n.s. |
Use of instrumental social support | 10.1 (3.2) | 8.8 (3) | T (157) = 2.69; p < 0.01 |
Active coping | 11.4 (2.4) | 9.9 (2.5) | T (157) = 4.02; p < 0.001 |
Denial | 5.6 (2) | 6.1 (1.9) | n.s. |
Religious coping | 8 (4.1) | 8.6 (4.2) | n.s. |
Humor | 8 (3.6) | 6.9 (2.8) | T (157) = 2.24; p < 0.05 |
Behavioral disengagement | 6.1 (1.9) | 7.4 (2.6) | T (157) = −3.3; p < 0.005 |
Restraint | 9.6 (2.8) | 9.6 (2.6) | n.s. |
Use of emotional social support | 9.8 (3.4) | 8.3 (3.1) | T (157) = 2.95; p < 0.005 |
Substance use | 5 (2) | 5.3 (2.4) | n.s. |
Acceptance | 11.7 (3.2) | 10.1 (3) | T (157) = 3.1; p < 0.005 |
Suppression of competing activities | 8.8 (2.4) | 8.6 (2.2) | n.s. |
Planning | 11.5 (2.8) | 9.6 (2.8) | T (157) = 4.17; p < 0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Teggi, R.; Finocchiaro, C.Y.; Ruggieri, C.; Gatti, O.; Rosolen, F.; Bussi, M.; Sarno, L. Alexithymia in Patients with Ménière Disease: A Possible Role on Anxiety and Depression. Audiol. Res. 2021, 11, 63-72. https://doi.org/10.3390/audiolres11010008
Teggi R, Finocchiaro CY, Ruggieri C, Gatti O, Rosolen F, Bussi M, Sarno L. Alexithymia in Patients with Ménière Disease: A Possible Role on Anxiety and Depression. Audiology Research. 2021; 11(1):63-72. https://doi.org/10.3390/audiolres11010008
Chicago/Turabian StyleTeggi, Roberto, Claudia Yvonne Finocchiaro, Claudio Ruggieri, Omar Gatti, Federica Rosolen, Mario Bussi, and Lucio Sarno. 2021. "Alexithymia in Patients with Ménière Disease: A Possible Role on Anxiety and Depression" Audiology Research 11, no. 1: 63-72. https://doi.org/10.3390/audiolres11010008
APA StyleTeggi, R., Finocchiaro, C. Y., Ruggieri, C., Gatti, O., Rosolen, F., Bussi, M., & Sarno, L. (2021). Alexithymia in Patients with Ménière Disease: A Possible Role on Anxiety and Depression. Audiology Research, 11(1), 63-72. https://doi.org/10.3390/audiolres11010008